FDA Approves Toripalimab for Nasopharyngeal Carcinoma Treatment

The FDA has approved toripalimab, a PD-1 inhibitor developed by Junshi Bio­sciences, for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC) in the US market. Co­herus Bio­Sciences holds the rights for the drug in the US and Canada and plans to launch it under the brand name Loqtorzi in the first quarter of 2024.